Govt should focus research on multi-drug resistant TB: panel

Image
Press Trust of India New Delhi
Last Updated : Mar 20 2017 | 7:28 PM IST
Noting that India has the "highest" tuberculosis burden in the world, a parliamentary panel has asked the government's medical research body to focus its research on multi-drug resistant TB in order to discover a potent drug combination to combat the disease.
At the same time, it has also asked Indian Council of Medical Research (ICMR) to prepare an action plan on antimicrobial resistance on a "priority" basis and work on standardisation of protocol to administer antibiotics.
It has also asked ICMR to take up a national level sensitisation process for the medical community.
"The committee recommends that ICMR should focus its research on multi-drug resistant TB strains with a view to discovering potent drug combinations combating MDRTB," the committee on Demands for Grants 2017-18 of Department of Health Research said.
It observed that India is the highest TB burden country in the world and the biggest challenge from health care point of view is increase in incidence of multi-drug resistant (MDRTB) and Extensively drug-resistant TB (XDRTB), especially in rural areas.
"Though the government has rolled out the administration of Bedaquiline, the first TB drug approval by the USFDA in over 40 years in six public health hospitals in the country to specifically treat MDRTB, a lot remains to be done to improve MDRTB treatment outcomes," said the committee chaired by Ram Gopal Yadav.
The World Health Organisation had recently said that MDRTB burden largely falls on three nations - China, India, and Russia - which together account for nearly half of all global cases.
The committee said antimicrobial resistance (AMR) is a "serious" issue which requires immediate attention and action.
"The committee believes that a dedicated action plan on antimicrobial resistance including antibiotic resistance needs to be prepared by ICMR on a priority basis.
"The committee strongly recommends for standardisation of protocol for the administration of antibiotics and expects that a process of sensitising the medical community about the perils of antibiotic resistance should be taken up on a national scale by involving medical and industry associations, medical academia, media and other groups," it said.
The committee also said "aggressive" awareness generation programmes regarding use of antibiotics without a prescription must be taken up to educate people in this regard.
AMR is the ability of a microorganism like bacteria and viruses to stop an antibiotic from working against it, as a result of which standard treatments become ineffective, infections persist and may spread to others.
The government has termed AMR as a "big" challenge and had recently said it is moving towards a mechanism of auditing prescriptions to monitor what drug is being prescribed and detailed guidelines.
The government has also announced the launch of a campaign next week involving four ministries to strategise to contain AMR.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 20 2017 | 7:28 PM IST

Next Story